The Risk Standardized Mortality Ratio for Late-Stage CKD and ESRD is an outcome measure to assess how well providers prevent mortality among patients with stage 4 or 5 CKD or ESRD. This measure assesses nephrology practices who care for adult Medicare Fee-for-Service (FFS) beneficiaries with late-stage CKD and ESRD.
- Measure TypeLevel Of AnalysisMAT output not attachedAttachedNumerator
The measure outcome is all-cause mortality within the measurement year. Mortality is defined as death for any reason within the measurement period for patients age 19 and older with Stage 4 CKD, Stage 5 CKD, or ESRD at risk during the measurement period. Hospice enrollment is a censoring event and mortality after enrollment is not counted to the outcome.
DenominatorThe cohort includes Medicare Fee-For-Service beneficiaries (patients) who are 19 years and older with Stage 4 CKD, Stage 5 CKD, or ESRD and who are being treated by a nephrology practice. Patients are not included if they are enrolled in Medicare hospice, or have had a kidney transplant within the past 12 months.
ExclusionsThe measure excludes patients with metastatic and advanced cancers, defined as specific cancer-related ICD-10 codes from an inpatient encounter.
All information required to stratify the measure resultsOffAll information required to stratify the measure resultsOffTesting Data Sources
- Measure StructureClinical Condition Topic Area
- Risk AdjustmentRisk adjustment approachOffRisk adjustment approachOffConceptual model for risk adjustmentOffConceptual model for risk adjustmentOff
- Current or planned use(s)Current Use(s)
- Most Recent Endorsement ActivityPrimary Care and Chronic Illness Spring 2023Endorsement StatusE&M Committee Rationale/Justification
Withdrawn by the developer due to the committee not passing the measure on evidence, a must-pass criterion.
- Do you have a secondary measure developer point of contact?OffThe measure developer is NOT the same as measure stewardOffSteward Organization Email
- Detailed Measure SpecificationsNoLogic ModelOffImpact and GapNoFeasibility assessment methodology and resultsNoAddress health equityNoMeasure’s use or intended useNo508 ComplianceOffIf no, attest that all information will be provided in other fields in the submission.Off
Effective March 27, 2023, the National Quality Forum (NQF) is no longer the consensus-based entity (CBE) funded through the Centers for Medicare & Medicaid Services (CMS) National Consensus Development and Strategic Planning for Health Care Quality Measurement Contract. Battelle has been selected to oversee the endorsement & maintenance (E&M) of clinical quality and cost/resource use measures. Since the Spring 2023 cycle launched at NQF, measures submitted to this E&M cycle continued along the prior E&M protocols that were in place at time of the Spring 2023 “Intent to Submit.” Battelle took over the E&M work for the Spring 2023 cycle when developers and/or stewards submitted their full measure information, which for CBE #3754, the most recent measure specifications can be found here: https://p4qm.org/sites/default/files/2023-06/3754_-ckd_esrd_mortality.zip
To close out this E&M cycle, Battelle published the Spring 2023 measures for pre-evaluation public commenting, convened the E&M standing committees for their measure evaluation meetings, launched the Spring 2023 post-comment period, convened the E&M committees for the post-comment meeting, convened the CSAC to render a final endorsement decision, and executed the appeals period.